EGFR Inhibitors for Treatment-Resistant Non-Small Cell Lung Cancer
Summary
USPTO has published patent application US20260108524A1 for methods of treating treatment-resistant non-small cell lung cancer using EGFR inhibitors. The application, filed October 16, 2023, names David A. Nathanson, Jonathan Tsang, and Timothy F. Cloughesy as inventors. CPC classifications include A61K 31/519, A61K 31/517, and A61P 35/00. This publication represents new intellectual property activity in the targeted oncology space.
“Disclosed herein are methods of treating treatment-resistant lung cancer, such as non-small cell lung cancer, using EGFR inhibitors.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 203 changes logged to date.
What changed
USPTO has published patent application US20260108524A1 for methods of treating treatment-resistant non-small cell lung cancer using EGFR inhibitors. The application names David A. Nathanson, Jonathan Tsang, and Timothy F. Cloughesy as inventors and was filed October 16, 2023. CPC classifications A61K 31/519, A61K 31/517, and A61P 35/00 indicate pharmaceutical compositions for cancer therapy.
Pharmaceutical companies and researchers in targeted oncology should note this publication as part of competitive landscape monitoring for EGFR inhibitor development. Patent applications do not themselves create compliance obligations but may affect IP strategy and freedom-to-operate analyses for entities developing similar therapeutics.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
EGFR INHIBITORS FOR TREATING LUNG CANCER
Application US20260108524A1 Kind: A1 Apr 23, 2026
Inventors
David A. Nathanson, Jonathan Tsang, Timothy F. Cloughesy
Abstract
Disclosed herein are methods of treating treatment-resistant lung cancer, such as non-small cell lung cancer, using EGFR inhibitors.
CPC Classifications
A61K 31/519 A61K 31/517 A61P 35/00
Filing Date
2023-10-16
Application No.
19120468
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.